rosuvastatin calcium

Trial	Outcome
NCT00127218 (2) [back to overview]	Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)
NCT00127218 (2) [back to overview]	Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries
NCT00239681 (6) [back to overview]	Time to Bone Fracture
NCT00239681 (6) [back to overview]	Time to Death Due to Any Cause
NCT00239681 (6) [back to overview]	Time to Development of Diabetes Mellitus
NCT00239681 (6) [back to overview]	Time to Major Cardiac Event (Cardiovascular Death, Stroke, Myocardial Infarction, Hospitalization Due to Unstable Angina or Arterial Revascularization)
NCT00239681 (6) [back to overview]	Time to Non-cardiovascular Death
NCT00239681 (6) [back to overview]	Time to Venous Thromboembolic Event
NCT00240331 (7) [back to overview]	Number of Randomised Participants That Died From Cardiovascular Cause
NCT00240331 (7) [back to overview]	Number of Randomised Participants That Died From Any Cause.
NCT00240331 (7) [back to overview]	Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).
NCT00240331 (7) [back to overview]	Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.
NCT00240331 (7) [back to overview]	Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)
NCT00240331 (7) [back to overview]	Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause
NCT00240331 (7) [back to overview]	Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC
NCT00296374 (72) [back to overview]	Urinary Albumin/Creatinine Ratio at Week 26
NCT00296374 (72) [back to overview]	Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
NCT00296374 (72) [back to overview]	Urinary Protein/Creatinine Ratio at Week 26.
NCT00296374 (72) [back to overview]	Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and TG
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and TG
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and TC
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and TC
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes
NCT00296374 (72) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
NCT00296374 (72) [back to overview]	Change From Baseline in eGFR at Week 52 [LOCF]
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
NCT00296374 (72) [back to overview]	Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C
NCT00296400 (72) [back to overview]	Urinary Albumin/Creatinine Ratio at Week 26
NCT00296400 (72) [back to overview]	Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
NCT00296400 (72) [back to overview]	Urinary Protein/Creatinine Ratio at Week 26.
NCT00296400 (72) [back to overview]	Urinary Protein/Creatinine Ratio at Week 52 [LOCF]
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26
NCT00296400 (72) [back to overview]	Change From Baseline in eGFR at Week 52 [LOCF]
NCT00296400 (72) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
NCT00296400 (72) [back to overview]	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26
NCT00296400 (72) [back to overview]	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
NCT00300430 (9) [back to overview]	Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]	Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]	Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study
NCT00300430 (9) [back to overview]	Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]	Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]	Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]	Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]	Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study
NCT00300430 (9) [back to overview]	Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study
NCT00300482 (8) [back to overview]	Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit
NCT00300482 (8) [back to overview]	Mean Percent Change in Triglycerides From Baseline to Final Visit
NCT00300482 (8) [back to overview]	Mean Percent Change in Total Cholesterol From Baseline to Final Visit
NCT00300482 (8) [back to overview]	Mean Percent Change in Non-low-density Lipoprotein Cholesterol (Non-HDL-C)From Baseline to Final Visit
NCT00300482 (8) [back to overview]	Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit
NCT00300482 (8) [back to overview]	Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit
NCT00300482 (8) [back to overview]	Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit
NCT00300482 (8) [back to overview]	Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Final Visit
NCT00329160 (4) [back to overview]	Percent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points
NCT00329160 (4) [back to overview]	Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV)
NCT00329160 (4) [back to overview]	Percent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein （LDL-C）
NCT00329160 (4) [back to overview]	Change From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion
NCT00355615 (13) [back to overview]	Percent Change in Apolipoprotein B (ApoB)
NCT00355615 (13) [back to overview]	Percent Change in LDL-C/HDL-C
NCT00355615 (13) [back to overview]	Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase
NCT00355615 (13) [back to overview]	Percent Change in Non-HDL-C at 12 Weeks
NCT00355615 (13) [back to overview]	Percent Change in Non-HDL-C/HDL-C
NCT00355615 (13) [back to overview]	Percent Change in TC/HDL-C
NCT00355615 (13) [back to overview]	Percent Change in Total Cholesterol (TC)
NCT00355615 (13) [back to overview]	Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment
NCT00355615 (13) [back to overview]	Percent Change in Triglycerides (TG)
NCT00355615 (13) [back to overview]	Percent Change in ApoB/ApoA-1
NCT00355615 (13) [back to overview]	Percent Change in Apolipoprotein A-1 (ApoA-1)
NCT00355615 (13) [back to overview]	Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)
NCT00355615 (13) [back to overview]	Percent Change in HDL-C
NCT00395486 (12) [back to overview]	Percentage Change of Total Cholesterol (TC)
NCT00395486 (12) [back to overview]	Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6
NCT00395486 (12) [back to overview]	Percentage Change of Apolipoprotein A1 (ApoA1)
NCT00395486 (12) [back to overview]	Percentage Change of Apolipoprotein B (ApoB)
NCT00395486 (12) [back to overview]	Percentage Change of Glucose Level
NCT00395486 (12) [back to overview]	Percentage Change of High-Density Lipoprotein-C (HDL-C)
NCT00395486 (12) [back to overview]	Percentage Change of Insulin Resistance Using HOMA-R
NCT00395486 (12) [back to overview]	Percentage of Subjects Reaching Their LDL-C Target Goal
NCT00395486 (12) [back to overview]	Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal
NCT00395486 (12) [back to overview]	Percentage Change of Triglycerides (TG)
NCT00395486 (12) [back to overview]	Percentage Change of Insulin Resistance Using QUICKI
NCT00395486 (12) [back to overview]	Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)
NCT00427960 (15) [back to overview]	The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category.
NCT00427960 (15) [back to overview]	The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category.
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline(week6) in TC
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline (Week 6)in Non-HDL-C
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio
NCT00427960 (15) [back to overview]	Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)
NCT00427960 (15) [back to overview]	The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio
NCT00427960 (15) [back to overview]	The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L
NCT00427960 (15) [back to overview]	The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L
NCT00427960 (15) [back to overview]	The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L
NCT00462748 (1) [back to overview]	Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus Rosuvastatin 5 mg Monotherapy (Full Analysis Set)
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in Total Cholesterol (Full Analysis Set)
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in Triglycerides (Full Analysis Set)
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in Very-low-density Lipoprotein Cholesterol (VLDL-C) (Full Analysis Set)
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus ABT-335 135 mg Monotherapy (Full Analysis Set)
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in Apolipoprotein B (ApoB) (Full Analysis Set)
NCT00463606 (9) [back to overview]	Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set)
NCT00463606 (9) [back to overview]	Median Percent Change From Baseline to the Final Visit in High Sensitivity C-reactive Protein (hsCRP) (Full Analysis Set)
NCT00473655 (9) [back to overview]	Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)
NCT00473655 (9) [back to overview]	HDL-C Increase
NCT00473655 (9) [back to overview]	ApoA1 Levels
NCT00473655 (9) [back to overview]	hsCRP Reduction
NCT00473655 (9) [back to overview]	LDL-C Reduction
NCT00473655 (9) [back to overview]	Non-HDL-C Reduction
NCT00473655 (9) [back to overview]	Total Cholesterol Reduction
NCT00473655 (9) [back to overview]	Adverse Events Reported
NCT00473655 (9) [back to overview]	ApoB Levels
NCT00479713 (10) [back to overview]	Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Triglycerides.
NCT00479713 (10) [back to overview]	Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment
NCT00479713 (10) [back to overview]	The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
NCT00479713 (10) [back to overview]	Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Apolipoprotein B
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Total Cholesterol
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
NCT00491530 (7) [back to overview]	Median Percent Change in Triglycerides From Baseline to Week 104 of This Open-Label Year 2 Study
NCT00491530 (7) [back to overview]	Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study
NCT00491530 (7) [back to overview]	Mean Percent Change in Total Cholesterol (Total-C) From Baseline to Week 104 of This Open-Label Year 2 Study
NCT00491530 (7) [back to overview]	Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study
NCT00491530 (7) [back to overview]	Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study
NCT00491530 (7) [back to overview]	Mean Percent Change in Direct Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study
NCT00491530 (7) [back to overview]	Percentage of Subjects Reporting Adverse Events During Combination Therapy in the Preceding Double-Blind Studies or in the Preceding Open-Label Year 1 Study or in This Open-Label Year 2 Study
NCT00525824 (13) [back to overview]	Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in LDL-C After 6 Weeks Monotherapy
NCT00525824 (13) [back to overview]	Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in TC/HDL-C After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment
NCT00620542 (16) [back to overview]	Non-HDL-C/HDL-C Blood Level
NCT00620542 (16) [back to overview]	Numbers of Patients Showing Regression in PAV
NCT00620542 (16) [back to overview]	Numbers of Patients Showing Regression in TAV
NCT00620542 (16) [back to overview]	Total Cholesterol Blood Level
NCT00620542 (16) [back to overview]	Total Cholesterol/HDL-C Blood Level
NCT00620542 (16) [back to overview]	Triglycerides Blood Level
NCT00620542 (16) [back to overview]	VLDL-C During the 104 Week Treatment Period
NCT00620542 (16) [back to overview]	LDL-C/HDL-C Blood Level
NCT00620542 (16) [back to overview]	LDL-C Blood Level
NCT00620542 (16) [back to overview]	HDL-C Blood Level
NCT00620542 (16) [back to overview]	Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)
NCT00620542 (16) [back to overview]	Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)
NCT00620542 (16) [back to overview]	Non-HDL-C Blood Level
NCT00620542 (16) [back to overview]	Apolipoprotein B Blood Level
NCT00620542 (16) [back to overview]	Apolipoprotein A-1 Blood Level
NCT00620542 (16) [back to overview]	Apoliprotein B/Apolipoprotein A-1 Blood Level
NCT00631189 (9) [back to overview]	Compare the Numbers of Patients Achieving the LDL-C Goal According to the National Cholesterol Education Program Adult Treatment Panel III (NCEP) ATP III) Guidelines for the Management of Dyslipidaemic Patients
NCT00631189 (9) [back to overview]	Compare the Percentage of HDL-C (High Density Lipoprotein Cholesterol) Variation From Baseline and After 8 Weeks of Treatment
NCT00631189 (9) [back to overview]	Compare the Percentage of Total Cholesterol Variation From Baseline and After 8 Weeks of Treatment
NCT00631189 (9) [back to overview]	Compare the Percentage of Variation From Baseline Apolipoprotein B/Apolipoprotein A1 Ratio and After 8 Weeks of Treatment
NCT00631189 (9) [back to overview]	Compare the Percentage of Variation of C-reactive Protein (CRP)
NCT00631189 (9) [back to overview]	Compare the Percentage of Variation of Phospholipase A2 (PLA2)
NCT00631189 (9) [back to overview]	Compare the Percentage of Variation From Baseline Triglycerides Values and After 8 Weeks
NCT00631189 (9) [back to overview]	To Evaluate Clinical and Laboratory Safety
NCT00631189 (9) [back to overview]	Change in Low Density Lipoprotein Cholesterol (LDL-C) Level After 8 Weeks
NCT00680017 (2) [back to overview]	Median Percent Change in Triglycerides From Baseline to Week 8.
NCT00680017 (2) [back to overview]	Mean Percent Change in High-Density Lipoprotein Cholesterol From Baseline to Week 8.
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Triglycerides (TG) at Week 6
NCT00683618 (15) [back to overview]	Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6
NCT00683618 (15) [back to overview]	Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6
NCT00683618 (15) [back to overview]	6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg
NCT00683618 (15) [back to overview]	Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6
NCT00747149 (1) [back to overview]	Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy
NCT00783263 (7) [back to overview]	Number of Participants in Each Stratum Who Reached Their Target LDL-C Level
NCT00783263 (7) [back to overview]	Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum
NCT00783263 (7) [back to overview]	Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels
NCT00783263 (7) [back to overview]	Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment
NCT00783263 (7) [back to overview]	Number of Participants Who Reached Their Target LDL-C Level
NCT00783263 (7) [back to overview]	Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl
NCT00783263 (7) [back to overview]	Number of Participants Who Reached the LDL-C Level of <70 mg/dl
NCT00815659 (40) [back to overview]	High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Basal Tumor Necrosis Factor (TNF) Level
NCT00815659 (40) [back to overview]	Basal Triglyceride Level
NCT00815659 (40) [back to overview]	Basal Total Cholesterol Level
NCT00815659 (40) [back to overview]	Basal Small HDL Subfraction Level
NCT00815659 (40) [back to overview]	Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Basal LDL-cholesterol Level
NCT00815659 (40) [back to overview]	Basal LDL-7 Level
NCT00815659 (40) [back to overview]	Basal LDL-5 Level
NCT00815659 (40) [back to overview]	Basal LDL-4 Level
NCT00815659 (40) [back to overview]	Basal LDL-3 Level
NCT00815659 (40) [back to overview]	Basal Intermediate HDL Subfraction Level
NCT00815659 (40) [back to overview]	Basal Interleukin 8 (IL-8) Level
NCT00815659 (40) [back to overview]	Basal Interleukin 6 (IL-6) Level
NCT00815659 (40) [back to overview]	Basal Interleukin 10 (IL-10) Level
NCT00815659 (40) [back to overview]	Basal Interleukin 1 (IL-1) Level
NCT00815659 (40) [back to overview]	Basal High Sensitivity C-reactive Protein (Hs-CRP) Level
NCT00815659 (40) [back to overview]	Basal HDL-cholesterol Level
NCT00815659 (40) [back to overview]	LDL-4 Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Triglyceride Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Total Cholesterol Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Number of Patients With Adverse Events
NCT00815659 (40) [back to overview]	Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Basal Large HDL Subfraction Level
NCT00815659 (40) [back to overview]	Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	LDL-7 Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	LDL-6 Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	LDL-5 Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	LDL-3 Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment
NCT00815659 (40) [back to overview]	Basal LDL-6 Level
NCT00815659 (40) [back to overview]	Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment
NCT00850460 (2) [back to overview]	Individualized Neuromuscular Quality of Life (INQoL) Mean Scores From Week 0 to Week 8
NCT00850460 (2) [back to overview]	Individualized Short Form-36 (SF-36) Mean Scores (Physical Component) From Week 0 to Week 8
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Triglycerides
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in TC/HDL-C Ratio
NCT00862251 (18) [back to overview]	Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Non-HDL-C/HDL-C Ratio
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).
NCT00862251 (18) [back to overview]	Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin
NCT00862251 (18) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Apo B/Apo A-I Ratio
NCT00862251 (18) [back to overview]	Percent Change From Baseline Apolipoprotein A-I (Apo A-I)
NCT00862251 (18) [back to overview]	Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)
NCT00862251 (18) [back to overview]	In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin
NCT00862251 (18) [back to overview]	In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)
NCT00862251 (18) [back to overview]	In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin
NCT00862251 (18) [back to overview]	In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in LDL-C/HDL-C Ratio
NCT00871351 (5) [back to overview]	Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)
NCT00871351 (5) [back to overview]	Percent Change in Total Lipids and Hs-CRP
NCT00871351 (5) [back to overview]	Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values
NCT00871351 (5) [back to overview]	Percent Change in LDL-C
NCT00871351 (5) [back to overview]	Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values
NCT00885495 (4) [back to overview]	Cmax of Rosuvastatin
NCT00885495 (4) [back to overview]	AUC of Rosuvastatin
NCT00885495 (4) [back to overview]	To Investigate the Effect of Rosuvastatin on the Steady State Pharmacokinetics of Darunavir/Ritonavir.
NCT00885495 (4) [back to overview]	To Compare the Change in Low-density Lipoprotein (LDL) Cholesterol With Rosuvastatin Therapy Alone, Darunavir/Ritonavir Therapy Alone and With the Co-administration of Rosuvastatin and Darunavir/Ritonavir.
NCT00908011 (1) [back to overview]	The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both Rosuvastatin and Ezetimibe.
NCT00929734 (4) [back to overview]	Relative Change in High-sensitivity C-reactive Protein
NCT00929734 (4) [back to overview]	Relative Change in Reactive Hyperemia Index (RHI)
NCT00929734 (4) [back to overview]	Relative Change in Interleukin 6
NCT00929734 (4) [back to overview]	Relative Change in FEV1
NCT00979121 (6) [back to overview]	Organ Failure Free Days at Day 14
NCT00979121 (6) [back to overview]	Changes in Plasma Concentrations of C-reactive Protein (CRP) From Baseline to Day 6 and Day 14
NCT00979121 (6) [back to overview]	Ventilator Free Days at Study Day 28
NCT00979121 (6) [back to overview]	ICU Free Days to Day 28
NCT00979121 (6) [back to overview]	Hospital Mortality to Day 60.
NCT00979121 (6) [back to overview]	Other Secondary Out-comes
NCT01011478 (8) [back to overview]	Overall Survival (OS)
NCT01011478 (8) [back to overview]	Second Non-colorectal Primary Cancer-free Interval
NCT01011478 (8) [back to overview]	Size of Colorectal Adenomas, Including Advanced Adenomas
NCT01011478 (8) [back to overview]	Toxicity Assessed by Adverse Events
NCT01011478 (8) [back to overview]	Recurrence-free Interval (RFI)
NCT01011478 (8) [back to overview]	Behavioral and Health Outcomes as Measured by SF-12 Component Scores, Global Quality-of-life Scale, and Symptom Checklist
NCT01011478 (8) [back to overview]	Disease-free Survival
NCT01011478 (8) [back to overview]	Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R)
NCT01068626 (6) [back to overview]	Change in Visceral Adipose Tissue Area Measured by Computed Tomography.
NCT01068626 (6) [back to overview]	Change in the Ratio Between Intra-abdominal and Subcutaneous Tissue Area Measured by CT.
NCT01068626 (6) [back to overview]	Change in Subcutaneous Adipose Tissue Area
NCT01068626 (6) [back to overview]	Change in Hepatic Fat Infiltration Measured by CT.
NCT01068626 (6) [back to overview]	Change in Body Weight
NCT01068626 (6) [back to overview]	Change in LDL
NCT01078675 (13) [back to overview]	Total Duration of Exposure
NCT01078675 (13) [back to overview]	Adverse Events
NCT01078675 (13) [back to overview]	Change From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)
NCT01078675 (13) [back to overview]	Percent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1
NCT01078675 (13) [back to overview]	Sexual Maturation by Tanner Staging at Baseline
NCT01078675 (13) [back to overview]	Sexual Maturation by Tanner Staging at Month 24
NCT01078675 (13) [back to overview]	Percent Change From Baseline in Height
NCT01078675 (13) [back to overview]	Sexual Maturation by Tanner Staging at Month 12
NCT01078675 (13) [back to overview]	Overal Treatment Adherence
NCT01078675 (13) [back to overview]	Percent Change From Baseline in LDL-C
NCT01078675 (13) [back to overview]	Single Dose PK - AUC(0-24)
NCT01078675 (13) [back to overview]	Single Dose PK - Cmax
NCT01078675 (13) [back to overview]	Single Dose PK - Tmax
NCT01105975 (17) [back to overview]	The Number of Episodes of Rashes at Any Time From Baseline Through Week 12
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity
NCT01105975 (17) [back to overview]	Change From Baseline to 12 Weeks Endpoint in Plasma Renin Activity
NCT01105975 (17) [back to overview]	Change From Baseline to 12 Weeks Endpoint in Serum Aldosterone
NCT01105975 (17) [back to overview]	Change From Baseline to 12 Weeks Endpoint in Serum Bicarbonate
NCT01105975 (17) [back to overview]	Change From Baseline to 12 Weeks Endpoint in Serum Potassium
NCT01105975 (17) [back to overview]	Change From Baseline to 12 Weeks Endpoint in Serum Sodium
NCT01105975 (17) [back to overview]	Change From Baseline to 18 Weeks Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) Score
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 and Placebo
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy
NCT01105975 (17) [back to overview]	Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Mass
NCT01105975 (17) [back to overview]	Pharmacokinetics - LY2484595 Area Under the Concentration-Time Curve (AUC) at Steady-State
NCT01105975 (17) [back to overview]	Change From Baseline to 12 Weeks Endpoint in Blood Pressure (BP)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo B (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in TC/HDL-C Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in TC/HDL-C Ratio (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Triglycerides (TG) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Triglycerides (TG) (Phase II)
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo A-I (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Hs-CRP (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in HDL-C (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)
NCT01178853 (1) [back to overview]	Percent Mean Change From Baseline of International Normalized Ratio (INR)
NCT01218802 (2) [back to overview]	Carotid IMT
NCT01218802 (2) [back to overview]	Bone Mineral Density (BMD)
NCT01241903 (1) [back to overview]	Platelet - Leukocyte Aggregates
NCT01299038 (1) [back to overview]	Mean Change of Tissue Factor Bearing Microparticles
NCT01420549 (1) [back to overview]	Reduction of LDL Cholesterol Levels
NCT01544309 (16) [back to overview]	Change From Baseline in 1,5-AG Level
NCT01544309 (16) [back to overview]	Change in HbA1c Level
NCT01544309 (16) [back to overview]	Percent Change in Non-HDL-C Level
NCT01544309 (16) [back to overview]	Rate of Patients Who Have Reached the Target LDL-C Level Specified in Japan Atherosclerosis Society Guidelines (JASGL) 2007
NCT01544309 (16) [back to overview]	Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)
NCT01544309 (16) [back to overview]	Percent Change in Insulin Level
NCT01544309 (16) [back to overview]	Percent Change in Blood Glucose Level (Fasting)
NCT01544309 (16) [back to overview]	Frequency of Serious Adverse Events (SAE)
NCT01544309 (16) [back to overview]	Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level
NCT01544309 (16) [back to overview]	Percent Change in 1,5-AG Level
NCT01544309 (16) [back to overview]	Change From Baseline in Insulin Level
NCT01544309 (16) [back to overview]	Change in Blood Glucose Level (Fasting)
NCT01544309 (16) [back to overview]	Change in HbA1c Level
NCT01544309 (16) [back to overview]	Number of Participants Stratified by Time to the Occurrence of Deterioration of Diabetic Treatment Status
NCT01544309 (16) [back to overview]	Occurrence of Deterioration of Diabetic Treatment Status
NCT01544309 (16) [back to overview]	Frequency of Cardiovascular Events (Coronary Artery Disease, Heart Failure, Cerebrovascular Disease, Peripheral Artery Disease and Aortic Disease)
NCT01567826 (10) [back to overview]	Intravascular Ultrasound (IVUS) Parameters
NCT01567826 (10) [back to overview]	Fractional Flow Reserve (FFR) Value
NCT01567826 (10) [back to overview]	Blood Chemistry - HsCRP
NCT01567826 (10) [back to overview]	Post PCI Cardiac Enzymes
NCT01567826 (10) [back to overview]	Lipiscan - Lipid Core Burden Index (LCBI)
NCT01567826 (10) [back to overview]	LCBI4mm Max
NCT01567826 (10) [back to overview]	Change in LCBI, Lesion
NCT01567826 (10) [back to overview]	Change in LCBI4mm Max
NCT01567826 (10) [back to overview]	Major Adverse Cardiac Events (MACE)
NCT01567826 (10) [back to overview]	Diameter Stenosis
NCT01660191 (6) [back to overview]	Changes to Glucose Metabolism - Fructosamine
NCT01660191 (6) [back to overview]	Changes in Major Lipid Parameters - VLDL Size
NCT01660191 (6) [back to overview]	Changes to Glucose Metabolism - HbA1c and Insulin
NCT01660191 (6) [back to overview]	Changes in Plasma CoQ10 Levels
NCT01660191 (6) [back to overview]	Changes HDL Particle Number and LDL Particle Number
NCT01660191 (6) [back to overview]	Changes in HDL and LDL Size
NCT01702987 (1) [back to overview]	Phosphocreatine Recovery
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
NCT01709500 (25) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
NCT01709500 (25) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01709500 (25) [back to overview]	Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01763866 (22) [back to overview]	Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12
NCT01763866 (22) [back to overview]	Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Triglycerides at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in HDL-C at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Change From Baseline in LDL-C at Week 12
NCT01763866 (22) [back to overview]	Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12
NCT01795937 (10) [back to overview]	Cmax,ss of Faldaprevir (Statins Part)
NCT01795937 (10) [back to overview]	Cmax,ss (Itraconazole Part)
NCT01795937 (10) [back to overview]	Cmax of Rosuvastatin
NCT01795937 (10) [back to overview]	Cmax of Atorvastatin (Statins Part)
NCT01795937 (10) [back to overview]	AUCτ,ss of Faldaprevir (Statins Part)
NCT01795937 (10) [back to overview]	AUCτ,ss (Itraconazole Part)
NCT01795937 (10) [back to overview]	AUC0-tz of Rosuvastatin
NCT01795937 (10) [back to overview]	AUC0-tz of Atorvastatin
NCT01795937 (10) [back to overview]	AUC0-∞ of Rosuvastatin (Statins Part)
NCT01795937 (10) [back to overview]	AUC0-∞ of Atorvastatin (Statins Part)
NCT01813357 (2) [back to overview]	Progression of Carotid Intima Media Thickness
NCT01813357 (2) [back to overview]	Rates of Adverse Events
NCT01837823 (15) [back to overview]	Mechanism of Reverse Cholesterol Transport
NCT01837823 (15) [back to overview]	MACE
NCT01837823 (15) [back to overview]	Lesion LCBI
NCT01837823 (15) [back to overview]	LCBI 4mm at Same Anatomical Site
NCT01837823 (15) [back to overview]	Fibrous Cap Thickness (FCT) by OCT
NCT01837823 (15) [back to overview]	Correlation of Baseline Lipid Parameters With Baseline LCBI4mm Max
NCT01837823 (15) [back to overview]	Correlation Between the Change in Fibrous Cap Thickness and Hs-CRP
NCT01837823 (15) [back to overview]	Correlation Between Plaque Morphology and HDL Functionality
NCT01837823 (15) [back to overview]	Change in Atheroma Volume
NCT01837823 (15) [back to overview]	Plaque Morphology as Related to Haptoglobin
NCT01837823 (15) [back to overview]	MACE
NCT01837823 (15) [back to overview]	IVUS Imaging Measures
NCT01837823 (15) [back to overview]	Inflammatory and Lipid Parameters
NCT01837823 (15) [back to overview]	Biomarker Release
NCT01837823 (15) [back to overview]	Maximal 4mm Lipid Core Burden Index (LCBI 4mm Max)
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in LDL-C, Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Non-HDL-C
NCT01890967 (10) [back to overview]	Number of Participants With an Injection Site Reaction
NCT01890967 (10) [back to overview]	Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)
NCT01890967 (10) [back to overview]	Number of Participants Who Develop Treatment Emergent Anti-LY3015014 Antibodies
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Free Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Lipoprotein(a) [Lp(a)]
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Total Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels
NCT01890967 (10) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady-State (AUC,ss) for LY3015014
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Apolipoprotein A1 (Apo A1), Apolipoprotein B (Apo B)
NCT01918332 (2) [back to overview]	sitDBP Changes at Week 8 From Baseline
NCT01918332 (2) [back to overview]	LDL-C Percentage Changes at Week 8 From Baseline
NCT02114697 (2) [back to overview]	Plaque Volume of Carotid Arteries
NCT02114697 (2) [back to overview]	Plaque Volume of Carotid Arteries
NCT02226198 (32) [back to overview]	TC (mg/dL)
NCT02226198 (32) [back to overview]	Non-HDL C/HDL C
NCT02226198 (32) [back to overview]	Non-HDL C (mmol/L)
NCT02226198 (32) [back to overview]	Non-HDL C (mg/dL)
NCT02226198 (32) [back to overview]	HDL-C (mmol/L)
NCT02226198 (32) [back to overview]	Weight
NCT02226198 (32) [back to overview]	Urinalysis Abnormalitites
NCT02226198 (32) [back to overview]	Tanner Stage
NCT02226198 (32) [back to overview]	Physical Exam Abnormalitites
NCT02226198 (32) [back to overview]	TG (mmol/L)
NCT02226198 (32) [back to overview]	LDL-Cholesterol (mmol/L)
NCT02226198 (32) [back to overview]	LDL-Cholesterol (mg/dL)
NCT02226198 (32) [back to overview]	LDL-C, Not on Apheresis (mmol/L)
NCT02226198 (32) [back to overview]	LDL-C, Not on Apheresis (mg/dL)
NCT02226198 (32) [back to overview]	Abnormal Vital Signs
NCT02226198 (32) [back to overview]	AE's Leading to Discontinuation
NCT02226198 (32) [back to overview]	ApoB (g/L)
NCT02226198 (32) [back to overview]	ApoB (mg/dL)
NCT02226198 (32) [back to overview]	ApoB/ApoA
NCT02226198 (32) [back to overview]	ECG Abnormalities
NCT02226198 (32) [back to overview]	LDL C/HDL C
NCT02226198 (32) [back to overview]	HDL-C (mg/dL)
NCT02226198 (32) [back to overview]	LDL-C From End of Placebo (mmol/L)
NCT02226198 (32) [back to overview]	LDL-C From End of Placebo (mg/dL)
NCT02226198 (32) [back to overview]	Height Z-score
NCT02226198 (32) [back to overview]	Height
NCT02226198 (32) [back to overview]	Adverse Events
NCT02226198 (32) [back to overview]	Abnormal Serum Levels
NCT02226198 (32) [back to overview]	Trough Concentrations
NCT02226198 (32) [back to overview]	TG (mg/dL)
NCT02226198 (32) [back to overview]	TC/HDL C
NCT02226198 (32) [back to overview]	TC (mmol/L)
NCT02317016 (14) [back to overview]	"Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration at Time t (AUC0-t) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291"
NCT02317016 (14) [back to overview]	Assessment of Minimum Plasma Concentration at Steady State (Css,Min) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together
NCT02317016 (14) [back to overview]	Assessment of the Metabolite to Parent Ratios of AUCtau (MRAUCtau) for AZ5104 and AZ7550 Following Administration of AZD9291 and Rosuvastatin Together
NCT02317016 (14) [back to overview]	Assessment of the Metabolite to Parent Ratios of Css,Max (MRCss,Max) for AZ5104 and AZ7550 Following Administration of AZD9291 and Rosuvastatin Together
NCT02317016 (14) [back to overview]	Assessment of Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together
NCT02317016 (14) [back to overview]	Assessment of Apparent Plasma Clearance (CL/F) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291
NCT02317016 (14) [back to overview]	Assessment of Apparent Plasma Clearance at Steady State (CLss/F) for AZD9291 Following Administration of AZD9291 and Rosuvastatin Together
NCT02317016 (14) [back to overview]	Assessment of Apparent Volume of Distribution (Vz/F) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291
NCT02317016 (14) [back to overview]	Assessment of AUC From Time Zero Extrapolated to Infinity for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291
NCT02317016 (14) [back to overview]	Assessment of Maximum Plasma Concentration (Cmax) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291
NCT02317016 (14) [back to overview]	Assessment of Terminal Elimination Half-life (t1/2[lambda_z]) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291
NCT02317016 (14) [back to overview]	Assessment of Time to Maximum Plasma Concentration (Tmax) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291
NCT02317016 (14) [back to overview]	Assessment of Area Under the Plasma Concentration-time Curve During the Dosing Interval (AUCtau) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together
NCT02317016 (14) [back to overview]	Assessment of Maximum Plasma Concentration at Steady State (Css,Max) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together
NCT02401256 (1) [back to overview]	Efavirenz AUC0-inf (Single Dose) and AUC0-24(Multiple Dose)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Vital Signs
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) >Upper Limite of Normal (ULN)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Growth, Height
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Physical Exams, Skin
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal ECG, Abnormalities
NCT02434497 (56) [back to overview]	Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg
NCT02434497 (56) [back to overview]	Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	The Number of Participants Who Experianced Adverse Events and Serious Adverse Events
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) >ULN
NCT02434497 (56) [back to overview]	Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L)
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) >ULN
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Growth, Weight
NCT02434497 (56) [back to overview]	Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)
NCT02476006 (11) [back to overview]	Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use
NCT02476006 (11) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02476006 (11) [back to overview]	Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections
NCT02476006 (11) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12
NCT02476006 (11) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12
NCT02476006 (11) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Triglycerides at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT02546323 (7) [back to overview]	Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average
NCT02546323 (7) [back to overview]	Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period
NCT02546323 (7) [back to overview]	Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA
NCT02546323 (7) [back to overview]	Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb
NCT02546323 (7) [back to overview]	Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA
NCT02546323 (7) [back to overview]	Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA
NCT02546323 (7) [back to overview]	Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)
NCT02574845 (3) [back to overview]	Maximum Concentration of Rosuvastatin (Cmax)
NCT02574845 (3) [back to overview]	Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT02574845 (3) [back to overview]	Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞)
NCT02586155 (15) [back to overview]	Change in Apolipoprotein A1 (ApoA-I) Concentration From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Incidence of All-cause Mortality
NCT02586155 (15) [back to overview]	Incidence of Hospitalization for Congestive Heart Failure (CHF)
NCT02586155 (15) [back to overview]	Change in Alkaline Phosphatase (ALP) From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Incidence of First Occurrence of Adjudication-confirmed Broadly Defined MACE
NCT02586155 (15) [back to overview]	Change in Apolipoprotein B (apoB) Concentration From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Change in C Reactive Protein (CRP) Concentration From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR <60 mL/Min/1.7m2)
NCT02586155 (15) [back to overview]	Change in Glucose From Baseline Over Time Between and Within Treatment Groups
NCT02586155 (15) [back to overview]	Change in HDL-C Concentration From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Change in Hemoglobin (Hb) A1c From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Change in LDL-C Concentration From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Change in Triglyceride (TG) Concentration From Baseline Over Time Within and Between Treatment Groups
NCT02586155 (15) [back to overview]	Incidence of First Occurrence of Adjudication-Confirmed Four-Point MACE
NCT02586155 (15) [back to overview]	Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE
NCT02704702 (3) [back to overview]	Area Under the Concentration-time Curve
NCT02704702 (3) [back to overview]	Maximum Observed Concentration
NCT02704702 (3) [back to overview]	Time to Reach Maximum Observed Plasma Concentration
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Hepatitis-related AEs
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Gallbladder-related AEs
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event
NCT02741245 (19) [back to overview]	Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)
NCT02741245 (19) [back to overview]	Percentage of Participants With Potential Hy's Law Condition
NCT02748057 (3) [back to overview]	Percentage of Participants Who Had Study Drug Discontinued Due to an AE
NCT02748057 (3) [back to overview]	Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT02748057 (3) [back to overview]	Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
NCT02841774 (2) [back to overview]	Treatment-emergent Adverse Events
NCT02841774 (2) [back to overview]	Mean Percent Change in Fasting LDL-cholesterol
NCT02854527 (12) [back to overview]	Maximum Concentration of Rosuvastatin (Cmax)
NCT02854527 (12) [back to overview]	Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)
NCT02854527 (12) [back to overview]	Area Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞)
NCT02854527 (12) [back to overview]	Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)
NCT02854527 (12) [back to overview]	Area Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞)
NCT02854527 (12) [back to overview]	Area Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞)
NCT02854527 (12) [back to overview]	Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)
NCT02854527 (12) [back to overview]	Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞)
NCT02854527 (12) [back to overview]	Area Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz)
NCT02854527 (12) [back to overview]	Maximum Concentration of Digoxin (Cmax)
NCT02854527 (12) [back to overview]	Maximum Concentration of Furosemide (Cmax)
NCT02854527 (12) [back to overview]	Maximum Concentration of Metformin (Cmax)
NCT02901067 (10) [back to overview]	Pulmonary Embolism
NCT02901067 (10) [back to overview]	Ventilator Free Days
NCT02901067 (10) [back to overview]	All-cause Mortality
NCT02901067 (10) [back to overview]	Incidence of Acute Lung Injury (ALI)
NCT02901067 (10) [back to overview]	Intensive Care Unit (ICU) Days
NCT02901067 (10) [back to overview]	Incidence of Arterial Thrombotic Complications: Myocardial Infarction (MI) and Cerebrovascular Accident (CVA).
NCT02901067 (10) [back to overview]	Incidence of Multiple Organ Failure (MOF)
NCT02901067 (10) [back to overview]	Fibrinolysis Phenotypes
NCT02901067 (10) [back to overview]	Incidence of VTE
NCT02901067 (10) [back to overview]	Incidence of Venous Thromboembolism (VTE)
NCT02984982 (24) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Total Cholesterol (TC) at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in External Elastic Membrane Volume at Week 36
NCT02984982 (24) [back to overview]	Number of Participants With Cardiovascular (CV) Adverse Events
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36
NCT03011775 (17) [back to overview]	Safety and Tolerability 4
NCT03011775 (17) [back to overview]	Lipid Metabolism 3
NCT03011775 (17) [back to overview]	Percutaneous Coronary Intervention [Coronary Revascularization]
NCT03011775 (17) [back to overview]	Cardiovascular Hospitalization
NCT03011775 (17) [back to overview]	Level of Insulin Resistance 2
NCT03011775 (17) [back to overview]	Lipid Metabolism 1
NCT03011775 (17) [back to overview]	Lipid Metabolism 2
NCT03011775 (17) [back to overview]	Carotic Atherosclerotic Lesions
NCT03011775 (17) [back to overview]	Сardiovascular Death
NCT03011775 (17) [back to overview]	Coronary Artery Bypass [Coronary Revascularization]
NCT03011775 (17) [back to overview]	Systemic Inflammation Level
NCT03011775 (17) [back to overview]	Safety and Tolerability 3
NCT03011775 (17) [back to overview]	Safety and Tolerability 2
NCT03011775 (17) [back to overview]	Safety and Tolerability 1
NCT03011775 (17) [back to overview]	Thickness of the Intima-media Complex
NCT03011775 (17) [back to overview]	Level of Insulin Resistance 1
NCT03011775 (17) [back to overview]	Diameter of Stenosis [Carotic Atherosclerotic Lesions]
NCT03019549 (3) [back to overview]	Pharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)
NCT03019549 (3) [back to overview]	Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin
NCT03019549 (3) [back to overview]	Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat
NCT03074630 (7) [back to overview]	Change in Plasma LDL Cholesterol
NCT03074630 (7) [back to overview]	Change in Plasma HDL Cholesterol
NCT03074630 (7) [back to overview]	Change in Plasma FFA
NCT03074630 (7) [back to overview]	Change in Peripheral Insulin Sensitivity
NCT03074630 (7) [back to overview]	Urinary Glucose Excretion
NCT03074630 (7) [back to overview]	Change in Total Cholesterol
NCT03074630 (7) [back to overview]	Change in Plasma Triglycerides
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T4 vs. R1)
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Cimetidine + R1 (T3) vs. R1)
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Probenecid + R1 (T4) vs. R1)
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Rifampin + R1 (T2) vs. R1)
NCT03307252 (12) [back to overview]	Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T4 vs. R1)
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Verapamil + R1 (T1) vs. R1)
NCT03307252 (12) [back to overview]	Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T1 vs. R1)
NCT03307252 (12) [back to overview]	Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T2 vs. R1)
NCT03307252 (12) [back to overview]	Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T3 vs. R1)
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T1 vs. R1)
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T2 vs. R1)
NCT03307252 (12) [back to overview]	Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T3 vs. R1)
NCT03311841 (18) [back to overview]	Effect of Rifampin on AUC0-last Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on Tmax Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on Cmax Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on t1/2 Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on AUC0-inf Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on CL/F Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on AUC0-24 Post-dose Period 2
NCT03311841 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to Last (AUC0-last) Post-dose Period 1
NCT03311841 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) Post-dose Period 1
NCT03311841 (18) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) Post-dose Period 1
NCT03311841 (18) [back to overview]	Apparent Volume of Distribution During the Terminal Phase (Vz/F) Post-dose Period 1
NCT03311841 (18) [back to overview]	Apparent Plasma Terminal Half-life (t1/2) Post-dose Period 1
NCT03311841 (18) [back to overview]	Apparent Clearance After Extravascular Administration (CL/F) Post-dose Period 1
NCT03311841 (18) [back to overview]	Effect of Rifampin on Vz/F Post-dose Period 2
NCT03311841 (18) [back to overview]	Effect of Rifampin on C24 Post-dose Period 2
NCT03311841 (18) [back to overview]	Time to Maximum Plasma Concentration (Tmax) Post-dose Period 1
NCT03311841 (18) [back to overview]	Plasma Concentration at 24 Hours (C24) Post-dose Period 1
NCT03311841 (18) [back to overview]	Maximum Plasma Concentration (Cmax) Post-dose Period 1
NCT03415178 (21) [back to overview]	Patient Perspective Questionnaire After the Last Injection (at Week 12): Single-Arm Period
NCT03415178 (21) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8, 12, 16: Single-Arm Period
NCT03415178 (21) [back to overview]	Percentage of Participants With a SYDNEY or Current Auto-Injector (AI)-Associated Product Technical Complaint (PTCs) (Overall and by Type) at the Supervised Injections on Week 0 (Day 1): Parallel-Arm Period
NCT03415178 (21) [back to overview]	Percentage of Participants With SYDNEY-Associated Product Technical Complaint (PTCs) (Overall and by Type) at the Unsupervised Injections : Single-Arm Period
NCT03415178 (21) [back to overview]	Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (by Type) at the Unsupervised Injections: Single-Arm Period
NCT03415178 (21) [back to overview]	Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm Period
NCT03415178 (21) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alirocumab : Parallel-Arm Period
NCT03415178 (21) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alirocumab: Single-Arm Period
NCT03415178 (21) [back to overview]	Total Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Parallel-Arm Period
NCT03415178 (21) [back to overview]	Total Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Single-Arm Period
NCT03415178 (21) [back to overview]	Number of Participants With Treatment-Emergent Anti-Alirocumab Antibodies (ADA) Positive Response According to ADA Status During Parallel-Arm Period: Single Arm Period
NCT03415178 (21) [back to overview]	Free Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Parallel-Arm Period
NCT03415178 (21) [back to overview]	Area Under the Curve-During the Dosing Interval Tau (AUC [0-tau]) : Parallel-Arm Period
NCT03415178 (21) [back to overview]	Area Under the Curve-During the Dosing Interval Tau (AUC [0-tau]) : Single-Arm Period
NCT03415178 (21) [back to overview]	Free Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Single-Arm Period
NCT03415178 (21) [back to overview]	Injection Experience Questionnaire at Initial Supervised Injection: Overall Ease of Use Scores: Parallel-Arm Period
NCT03415178 (21) [back to overview]	Injection-Treatment Acceptance Questionnaire (I-TAQ©) After Last Injection (at Week 12) - Overall Acceptance Scores: Single-Arm Period
NCT03415178 (21) [back to overview]	Maximum Serum Alirocumab Concentration Observed - Cmax : Parallel-Arm Period
NCT03415178 (21) [back to overview]	Maximum Serum Alirocumab Concentration Observed - Cmax : Single-Arm Period
NCT03415178 (21) [back to overview]	Number of Participants With Treatment-Emergent Anti-Alirocumab Antibodies (ADA) Positive Response: Parallel-Arm Period
NCT03415178 (21) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 4: Parallel-Arm Period
NCT03510715 (13) [back to overview]	Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48
NCT03510715 (13) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein A1 at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Total Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level <130 mg/dL (3.37 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level Lower Than (<) 130 mg/dL (3.37 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: ITT Estimand
NCT03510884 (44) [back to overview]	OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: On-treatment Estimand
NCT03510884 (44) [back to overview]	Change From Baseline in Cogstate Battery Test - Overall Composite Score at Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]	DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Total Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	Number of Participants With Tanner Staging at Baseline and Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 130 mg/dL (3.37 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 110 mg/dL (2.84 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved at Least 30 Percent (%) Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Achieved at Least 30% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein A1 at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Weeks 12, and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Lipoprotein (a) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Fasting Triglycerides at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein B at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03510884 (44) [back to overview]	DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03510884 (44) [back to overview]	DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: On-treatment Estimand
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Furosemide)
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Furosemide)
NCT04590937 (12) [back to overview]	Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax, Rosuvastatin)
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Digoxin)
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Digoxin)
NCT04590937 (12) [back to overview]	Maximum Measured Concentration of Digoxin in Plasma (Cmax, Digoxin)
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Rosuvastatin)
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Metformin)
NCT04590937 (12) [back to overview]	Maximum Measured Concentration of Furosemide in Plasma (Cmax, Furosemide)
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin)
NCT04590937 (12) [back to overview]	Maximum Measured Concentration of Metformin in Plasma (Cmax, Metformin)
NCT04590937 (12) [back to overview]	Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Rosuvastatin)
NCT04608344 (8) [back to overview]	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
NCT04608344 (8) [back to overview]	PK Parameter: Cmax of ATV, PRA, and ROS
NCT04608344 (8) [back to overview]	PK Parameter: Cmax of ATV, PRA, and ROS
NCT04608344 (8) [back to overview]	PK Parameter: AUCinf of ATV, PRA, and ROS
NCT04608344 (8) [back to overview]	PK Parameter: AUCinf of ATV, PRA, and ROS
NCT04608344 (8) [back to overview]	Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS
NCT04608344 (8) [back to overview]	Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS
NCT04608344 (8) [back to overview]	Percentage of Participants With Severity Grade 3 or Above Treatment-Emergent Laboratory Abnormalities
NCT04621227 (9) [back to overview]	Number of Participants With Laboratory Abnormalities (Without Regard to Baseline [BL] Abnormality)
NCT04621227 (9) [back to overview]	Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9)
NCT04621227 (9) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7
NCT04621227 (9) [back to overview]	AUClast of Midazolam in Periods 2, 5 and 8
NCT04621227 (9) [back to overview]	Change From Baseline in Body Weight
NCT04621227 (9) [back to overview]	Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria
NCT04621227 (9) [back to overview]	Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS)
NCT04621227 (9) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04621227 (9) [back to overview]	Number of Participants With Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria
NCT04846231 (4) [back to overview]	Percent Change in LDL-C From Baseline for Rosuvastatin 5mg Daily Compared With Placebo and Each Dietary Supplement.
NCT04846231 (4) [back to overview]	The Percent Change in HDL-C, Total Cholesterol, and Triglycerides for Placebo vs the Dietary Supplements.
NCT04846231 (4) [back to overview]	Percent Change in HDL-C, Total Cholesterol, and Triglycerides for Rosuvastatin vs Dietary Supplements.
NCT04846231 (4) [back to overview]	Percent Change in hsCRP for Rosuvastatin vs Dietary Supplements.
NCT05045638 (7) [back to overview]	AUC From Time Zero to Infinity (AUCinf) of Rosuvastatin
NCT05045638 (7) [back to overview]	AUCinf of Sotorasib
NCT05045638 (7) [back to overview]	AUClast of Sotorasib
NCT05045638 (7) [back to overview]	Cmax of Sotorasib
NCT05045638 (7) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin
NCT05045638 (7) [back to overview]	Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rosuvastatin
NCT05045638 (7) [back to overview]	Number of Participants Reporting Any Treatment-Emergent Adverse Events (TEAEs)

[back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top]